Literature DB >> 14699148

Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing.

Maria Malanga1, Felix R Althaus.   

Abstract

Regulating the topological state of DNA is a vital function of the enzyme DNA topoisomerase I. However, when acting on damaged DNA, topoisomerase I may get trapped in a covalent complex with nicked DNA (stalled topoisomerase I), that, if unrepaired, may lead to genomic instability or cell death. Here we show that ADP-ribose polymers target specific domains of topoisomerase I and reprogram the enzyme to remove itself from cleaved DNA and close the resulting gap. Two members of the poly(ADP-ribose) polymerase family, PARP-1 and 2, act as poly(ADP-ribose) carriers to stalled topoisomerase I sites and induce efficient repair of enzyme-associated DNA strand breaks. Thus, by counteracting topoisomerase I-induced DNA damage, PARP-1 and PARP-2 act as positive regulators of genomic stability in eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14699148     DOI: 10.1074/jbc.C300437200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

Review 2.  Targeting Topoisomerase I in the Era of Precision Medicine.

Authors:  Anish Thomas; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.

Authors:  Evan R Guggenheim; Dong Xu; Christiana X Zhang; Pamela V Chang; Stephen J Lippard
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

Review 4.  Poly-ADP-ribose polymerase: machinery for nuclear processes.

Authors:  Colin Thomas; Alexei V Tulin
Journal:  Mol Aspects Med       Date:  2013-04-25

5.  Poly(ADP-ribosyl)ation during chromatin remodeling steps in rat spermiogenesis.

Authors:  Mirella L Meyer-Ficca; Harry Scherthan; Alexander Bürkle; Ralph G Meyer
Journal:  Chromosoma       Date:  2005-04-19       Impact factor: 4.316

Review 6.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Authors:  Janelle M Hoskins; Gary L Rosner; Mark J Ratain; Howard L McLeod; Federico Innocenti
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

8.  Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Authors:  Junko Murai; Yiping Zhang; Joel Morris; Jiuping Ji; Shunichi Takeda; James H Doroshow; Yves Pommier
Journal:  J Pharmacol Exp Ther       Date:  2014-03-20       Impact factor: 4.030

9.  Glutamate regulates the activity of topoisomerase I in mouse cerebellum.

Authors:  Eldar Zehorai; Erez Eitan; Michal Hershfinkel; Israel Sekler; Esther Priel
Journal:  Mol Neurobiol       Date:  2008-11-04       Impact factor: 5.590

Review 10.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.